Bioymifi suppresses Burkitt’s lymphoma cell line proliferation via cell cycle arrest and apoptosis

Abstract

Purpose: To find a new treatment alternative for Burkitt’s lymphoma, one of the B cell-derived non Hodgkin's lymphomas that has an extremely aggressive growth profile with a high mortality rate. Methods: Bioymifi (death receptor agonist) was administered at various doses to Human Burkitt's Lymphoma Raji cell lines, and cell proliferation was evaluated using XTT analysis. Apoptosis induction and cell cycle analysis were assessed using flow cytometry. Results: Bioymifi exhibited good cytotoxicity in Raji cell lines with IC50 value of 29.5 µM. Furthermore, results of apoptosis induction and cell cycle analysis indicated that Bioymifi had potent anti-proliferative activity through sub-S cell cycle arrest and stimulation of apoptosis (p < 0.05). Conclusion: Bioymifi has anticancer potentials against Human Burkitt's Lymphoma Raji cell lines. Further pharmacological studies will be required to establish the mechanism of action.